LPTX - Leap Therapeutics/BeiGene initiates DKN-01+tislelizumab combination mid-stage study in gastric cancer

Leap Therapeutics (LPTX) up 7.2% in premarket, and BeiGene, (BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap's DKN-01, in combination with latter's tislelizumab, with or without chemotherapy in patients with gastric or gastroesophageal junction cancer (G/GEJ).The 72-subject trial is designed to evaluate safety, tolerability, and efficacy of the combination therapy of intravenous DKN-01 and tislelizumab ± CAPOX (capecitabine + oxaliplatin) in G/GEJ adenocarcinoma patients.Leap is conducting this combination study in the U.S. as part of an exclusive license agreement with BeiGene.

For further details see:

Leap Therapeutics/BeiGene initiates DKN-01+tislelizumab combination mid-stage study in gastric cancer